Recipharm completes US biologics acquisitions


Recipharm, a leading global contract development and manufacturing organisation (CDMO), announces the closing of its acquisitions of advanced therapy CDMO Arranta Bio and virotherapy CDMO Vibalogics. 

Article Summary

Recipharm announced the acquisition of Arranta Bio and Vibalogics. With this acquisition, Recipharm strengthens its presence in the Biologics market, with a particular focus on drug substance manufacturing of novel ATMPs (advanced therapy medicinal products). The acquisitions also enable Recipharm to establish a robust base in the US, with facilities in Boxborough, MA, and provide a platform from which to build its capabilities in new biologics modalities.

Both CDMOs have established specialisms within the biologics industry. Boxborough-based Arranta Bio is a leader in mRNA clinical production capabilities and delivering microbiome therapeutic products. Vibalogics holds a prominent position in the manufacture of oncolytic viruses, viral vaccines and gene therapies, offering process and analytical development, manufacturing, testing and fill-finish services from facilities in Cuxhaven, Germany as well as Boxborough, MA.

Marc Funk, CEO of Recipharm, said: “This acquisition is an important step in growing our Biologics business and developing our US presence. We will be building on the pioneering excellence which lies at the heart of these companies and providing drug developers in the Biologics market with scientifically differentiated CDMO services and expertise for ATMPs.”

“We are thrilled to be closing both acquisitions and look forward to welcoming the Arranta Bio and Vibalogics teams into the Recipharm organization,” he adds.

About Recipharm 

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing almost 9,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, pharmaceutical product development and development and manufacturing of medical devices. Recipharm manufactures several hundred different products for customers ranging from big pharma to smaller research and development companies. Recipharm’s annual turnover is approximately SEK 11 billion. The company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden.

(Source: Recipharm, 11th April 2022)



Leave A Comment

Leave a Reply

Your email address will not be published.